Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial

被引：0
|
作者：
O'Shaughnessy, J. [1 ]
Wright, G. S. [2 ]
Thummala, A. [3 ]
Danso, M. [4 ]
Popovic, L. S. [5 ]
Pluard, T. [6 ]
Han, H. S. [7 ]
Vojnovic, Z. [8 ]
Vasev, N. [9 ]
Ma, L. [10 ]
Richards, D. A. [11 ]
Wilks, S. [12 ]
Milenkovic, D. M. [13 ]
Sorrentino, J. A. [14 ]
Yang, Z. [15 ]
Horton, J. K. [16 ]
Tan, A. R. [17 ]
机构：
[1] Texas Oncol Baylor Sammons Canc Ctr, Med Oncol, Dallas, TX USA
[2] Florida Canc Specialists, Oncol, St Petersburg, FL USA
[3] US Oncol Res, Comprehens Canc Ctr Nevada, Med Oncol, Las Vegas, NV USA
[4] Virginia Oncol Associates, Med Oncol, Norfolk, VA USA
[5] Oncol Inst Vojvodina, Med Oncol, Sremska Kamenica, Serbia
[6] St Lukes Primary Care Plaza, Med Oncol, Kansas City, MO USA
[7] H Lee Moffitt Canc Ctr & Res Inst, McKinley Outpatient Clin, Breast Oncol, Tampa, FL USA
[8] OB Opca Boln Varazdin Gen Hosp, Dept Oncol, Varazhdin, Croatia
[9] UCRO, Dept Oncol, Skopje, Macedonia
[10] Rocky Mt Canc Ctr LLP, Med Oncol, Denver, CO USA
[11] Texas Oncol PA, Med Oncol, Houston, TX USA
[12] Texas Oncol San Antonio Northeast, Med Oncol, San Antonio, TX USA
[13] Univ Nis, Clin Ctr Nis, Clin Oncol, Nish, Serbia
[14] G1 Therapuet Inc, Translat Med, Res Triangle Pk, NC USA
[15] G1 Therapuet Inc, Biostat, Res Triangle Pk, NC USA
[16] G1 Therapuet Inc, Clin Dev, Res Triangle Pk, NC USA
[17] Atrium Hlth, Levine Canc Inst, Med Oncol, Charlotte, NC USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA22
引用
收藏
页码：860 / +
页数：2
相关论文
共 50 条
  • [31] Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results
    Seneviratne, Lasika C.
    Harnden, Kathleen Kiernan
    Blau, Sibel
    Danso, Michael A.
    Berz, David
    Guaqueta, Delia Constanza
    Schwerkoske, John F.
    O'Shaughnessy, Joyce
    Patt, Debra A.
    Bardia, Aditya
    McCann, Kelly Elizabeth
    Beelen, Andrew Paul
    Zhang, Jingshan
    Yi, John S.
    Hurvitz, Sara A.
    Mardones, Mabel Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Evaluation of gemcitabine plus carboplatin in pretreated, metastatic breast cancer patients: Final analysis of a phase II trial
    Laessig, D.
    Vehling-Kaiser, U.
    Stemmler, H. J.
    Fasching, P.
    Melchert, F.
    Koelbl, H.
    Stauch, M.
    Scharl, A.
    Morack, G.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer
    Barnato, Sara E.
    Jeruss, Jacqueline Sara
    Bethke, Kevin P.
    Hansen, Nora M.
    Khan, Seema Ahsan
    Von Roenn, Jamie H.
    Rosen, Steven T.
    Gradishar, William John
    Siziopikou, Kalliopi P.
    Meservey, Caitlin
    Kaklamani, Virginia G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase Ib/II trial.
    Campone, Mario
    Ferrero, Jean-Marc
    Gunzer, Katharina
    Priou, Frank
    Dubreuil, Patrice
    Mansfield, Colin
    Moussy, Alain
    Hermine, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic or recurrent breast cancer patients with triple negative disease
    Cowherd, Stacy
    Melin, Susan
    Akman, Steven
    Cole, John
    Lawrence, Julia
    CANCER RESEARCH, 2014, 74 (19)
  • [36] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
    Yardley, Denise A.
    Brufsky, Adam
    Coleman, Robert E.
    Conte, Pierfranco F.
    Cortes, Javier
    Glueck, Stefan
    Nabholtz, Jean-Mark A.
    O'Shaughnessy, Joyce
    Beck, Robert M.
    Ko, Amy
    Renschler, Markus F.
    Barton, Debora
    Harbeck, Nadia
    TRIALS, 2015, 16
  • [37] Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
    Denise A. Yardley
    Adam Brufsky
    Robert E. Coleman
    Pierfranco F. Conte
    Javier Cortes
    Stefan Glück
    Jean-Mark A. Nabholtz
    Joyce O’Shaughnessy
    Robert M. Beck
    Amy Ko
    Markus F. Renschler
    Debora Barton
    Nadia Harbeck
    Trials, 16
  • [38] Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer.
    Moreno-Aspitia, A.
    Rowland, K. M.
    Liu, H.
    Hillman, D. W.
    Stella, P. J.
    Perez, E. A.
    CANCER RESEARCH, 2011, 71
  • [39] nab-paclitaxel plus carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial
    Yardley, D.
    Coleman, R.
    Conte, P.
    Cortes, J.
    Brufsky, A.
    Shtivelband, M.
    Young, R.
    Bengala, C.
    Ali, H.
    Eakel, J.
    Schneeweiss, A.
    Merino, L. de la Cruz
    Wilks, S.
    O'Shaugnessy, J.
    Gluck, S.
    Li, H.
    Beck, R.
    Barton, D.
    Harbeck, N.
    CANCER RESEARCH, 2017, 77
  • [40] RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial
    Singh, Jasmeet Chadha
    Stein, Stacy
    Volm, Matthew
    Smith, Julia Anne
    Adams, Sylvia
    Meyers, Marlene
    Speyer, James L.
    Novik, Yelena
    Schneider, Robert
    Formenti, Sylvia
    Muggia, Franco
    Jhaveri, Komal L.
    Goldberg, Judith D.
    Heese, Scott
    Li, Xiaochun
    Davis, Samantha
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345